

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Monia Marchetti*, Jon Salmanton-García[†], Shaimaa El-Ashwah, Luisa Verga, Federico Itri, Zdeněk Ráčil, Julio Dávila-Valls, Sonia Martín-Pérez, Jaap Van Doesum, Francesco Passamonti, Ghaith Abu-Zeinah, Francesca Farina, Alberto López-García, Giulia Dragonetti, Chiara Cattaneo, Maria Gomes Da Silva, Yavuz M. Bilgin, Pavel Žák, Verena Petzer, Andreas Glenthøj, Ildefonso Espigado, Caterina Buquicchio, Valentina Bonuomo, Lucia Prezioso, Stef Meers, Rafael Duarte, Rui Bergantim, Ozren Jaksic, Natasha Čolović, Ola Blennow, Martin Cernan, Martin Schönlein, Michail Samarkos, Maria Enza Mitra, Gabriele Magliano, Johan Maertens, Marie-Pierre Ledoux, Moraima Jiménez, Fatih Demirkan, Graham P. Collins[†], Alba Cabirta, Stefanie K. Gräfe, Anna Nordlander, Dominik Wolf, Elena Arellano, Raul Cordoba, Michaela Hanakova, Giovanni Paolo Maria Zambrotta, Raquel Nunes Rodrigues, Giulia Limberti, Francesco Marchesi, Oliver A. Cornely and Livio Pagano

Abstract

Background: Patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) typically incur high rates of infections and both drugs and comorbidities may modulate infection risk.

Objectives: The present study aims to assess the effect of immunosuppressive agents on clinical outcomes of MPN patients affected by the coronavirus disease 2019 (COVID-19).

Design: This is an observational study.

Methods: We specifically searched and analyzed MPN patients collected by EPICOVIDEHA online registry, which includes individuals with hematological malignancies diagnosed with COVID-19 since February 2020.

Results: Overall, 398 patients with MPN were observed for a median of 76 days [interquartile range (IQR): 19–197] after detection of SARS-CoV2 infection. Median age was 69 years (IQR: 58–77) and 183 individuals (46%) had myelofibrosis (MF). Overall, 121 patients (30%) of the whole cohort received immunosuppressive therapies including steroids, immunomodulatory drugs, or JAK inhibitors. Hospitalization and consecutive admission to intensive care unit was required in 216 (54%) and 53 patients (13%), respectively. Risk factors for hospital admission were identified by multivariable logistic regression and include exposure to immunosuppressive therapies [odds ratio (OR): 2.186; 95% confidence interval (CI): 1.357–3.519], age ≥ 70 years, and comorbidities. The fatality rate was 22% overall and the risk of death was independently increased by age ≥ 70 years [hazard ratio (HR): 2.191; 95% CI: 1.363–3.521], previous comorbidities, and exposure to immunosuppressive therapies before the infection (HR: 2.143; 95% CI: 1.363–3.521).

Conclusion: COVID-19 infection led to a particularly dismal outcome in MPN patients receiving immunosuppressive agents or reporting multiple comorbidities. Therefore, specific preventive strategies need to be tailored for such individuals.

Ther Adv Hematol

2023, Vol. 14: 1–15

DOI: 10.1177/
20406207231154706

© The Author(s), 2023.
Article reuse guidelines:
sagepub.com/journals-
permissions

Correspondence to:
Jon Salmanton-García
Department I of Internal
Medicine, Excellence
Center for Medical
Mycology (ECMM), Faculty
of Medicine and University
Hospital Cologne,
University of Cologne,
Cologne, Germany.

Cologne Excellence
Cluster on Cellular Stress
Responses in Aging-
Associated Diseases
(CECAD), Faculty of
Medicine and University
Hospital Cologne,
University of Cologne,
Cologne, Germany
jon.salmanton-garcia@uk-koeln.de

Monia Marchetti
Giulia Limberti
Azienda Ospedaliera
Nazionale SS. Antonio e
Biagio e Cesare Arrigo,
Alessandria, Italy

Shaimaa El-Ashwah
Oncology Center,
Mansoura University,
Mansoura, Egypt

Luisa Verga
Giovanni Paolo Maria Zambrotta
Azienda Ospedaliera San
Gerardo–Monza, Monza,
Italy; Università Milano-
Bicocca, Milan, Italy

Federico Itri
San Luigi Gonzaga
Hospital–Orbassano,
Orbassano, Italy

Zdeněk Ráčil
Michaela Hanakova
Institute of Hematology
and Blood Transfusion,
Prague, Czech Republic

Julio Dávila-Valls
Sonia Martín-Pérez
Hospital Nuestra Señora
de Sonsoles, Ávila, Spain

Jaap Van Doesum
University Medical Center
Groningen, Groningen, The
Netherlands

Francesco Passamonti
University Insubria,
Varese, Italy

Ghaith Abu-Zeinah

Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA

Francesca Farina

IRCCS Ospedale San Raffaele, Milan, Italy

Alberto López-García

Health Research Institute IIS-FJD, Fundación Jimenez Diaz University Hospital, Madrid, Spain

Giulia Dragonetti

Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Rome, Italy

Chiara Cattaneo

Hematology Unit, ASST-Spedali Civili, Brescia, Italy

Maria Gomes Da Silva

Raquel Nunes Rodrigues Portuguese Institute of Oncology, Lisbon, Portugal

Yavuz M. Bilgin

Department of Internal Medicine, ADRZ, Goes, The Netherlands

Pavel Žák

University Hospital Hradec Králové, Hradec Králové, Czech Republic

Verena Petzer

Dominik Wolf Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria

Andreas Glenthøj

Department of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark

Ildelfonso Espigado

Department of Hematology, University Hospital Virgen Macarena-University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC) and Departamento de Medicina, Universidad de Sevilla, Seville, Spain

Caterina Buquicchio

Ematologia con Trapianto, Ospedale Dimiccoli Barletta, Barletta, Italy

Valentina Bonuomo

Section of Hematology, Department of Medicine, University of Verona, Verona, Italy

Lucia Prezioso

Hematology and Bone Marrow Unit, Hospital University of Parma, Parma, Italy

Stef Meers

AZ KLINA, Brasschaat, Belgium

Plain language summary

EPICOVIDEHA registry reports inferior outcomes of COVID-19 in patients with Philadelphia-negative chronic myeloproliferative neoplasms receiving immunosuppressive therapies.

Patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) incur high rates of infections during the course of their disease.

The present study was aimed at assessing which patient characteristics predicted a worse outcome of SARS-CoV-2 infection in individuals with MPN.

To pursue this objective, the researchers analyzed the data collected by EPICOVIDEHA, an international online registry, which includes individuals with hematological malignancies diagnosed with COVID-19 since February 2020.

The database provided clinical data of 398 patients with MPN incurring COVID-19:

- Patients were mostly elderly (median age was 69 years);
- Forty-six percent of them were affected by myelofibrosis, which is the most severe MPN;
- Moreover, 32% were receiving immunosuppressive therapies (JAK inhibitors, such as ruxolitinib, steroids, or immunomodulatory IMiD drugs, such as thalidomide) before COVID-19.

Hospitalization was required in 54% of the patients, and the risk of being hospitalized for severe COVID-19 was independently predicted by

- Older age;
- Comorbidities;
- Exposure to immunosuppressive therapies.

Overall, 22% of MPN patients deceased soon after COVID-19 and the risk of death was independently increased over twofold by

- Older age;
- Comorbidities;
- Exposure to immunosuppressive therapies before the infection.

In conclusion, COVID-19 infection led to a particularly dismal outcome in MPN patients receiving immunosuppressive agents, including JAK inhibitors, or reporting multiple comorbidities. Therefore, specific preventive strategies need to be tailored for such individuals.

Keywords: COVID-19, essential thrombocytemia, hydroxyurea, myelofibrosis, Philadelphia-negative chronic myeloproliferative neoplasms, polycythemia vera, ruxolitinib, SARS-CoV-2

Received: 17 August 2022; revised manuscript accepted: 17 January 2023.

Introduction

Coronavirus disease 2019 (COVID-19) is a public health emergency of international concern since February 2020. It is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a rapidly spreading novel coronavirus which principally causes pneumonia and respiratory failure, alongside damage to several organs by inflammatory and pro-thrombotic pathways.^{1,2} Age and comorbidity were reported to independently predict the fatality rate (FR) in COVID-19, and individuals affected by baseline

hematological malignancies (HM) were reported to incur twofold higher mortality compared with the general population.^{3,4}

Philadelphia-negative chronic myeloproliferative neoplasms (MPN) represent one-third of myeloid malignancies and, due to its indolent course, prevalence is high (50 per 100,000 inhabitants).⁵ MPN is characterized by thrombocytosis, leukocytosis, and erythrocytosis, but they may also present with or develop cytopenias, that associate with adverse clinical outcomes. Arterial and

venous thromboses are the most common complications of MPNs, due to intrinsic abnormalities of endothelial cells as well as altered platelet and leukocyte function, which may be exacerbated by infections. Of significance, the risk of viral infections is threefold higher in MPN compared with matched controls.^{6,7} Based on the above clinical features, MPN patients with COVID-19 are expected to have an increased risk for severe outcomes.

The present study aimed to assess clinical outcomes of COVID-19 in patients with MPN. More specifically, we aimed at testing the impact of previous therapies for MPN onto SARS-CoV-2 infection outcomes and to identify the more frail subgroups potentially requiring intensified preventive measures (e.g. application of preventive monoclonal antibodies).

Methods

In February 2020, an international cooperative registry, named EPICOVIDEHA, was initiated by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA).⁸ EPICOVIDEHA is a multicenter, noninterventional, observational study approved by the local Institutional Review Board and Ethics Committee of the Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Università Cattolica del Sacro Cuore of Rome, Italy (Study ID: 3226). The corresponding local ethics committee of each participating institution may approve additionally the EPICOVIDEHA study when applicable. EPICOVIDEHA is registered at <http://www.clinicaltrials.gov>, with the identifier NCT 04733729.

Researchers from different countries were invited to retrospectively review all episodes of COVID-19 disease occurring in patients with blood cancers identified at their institutions from February 2020 onward. The EPICOVIDEHA electronic case report form is available at www.clinicalsurveys.net (EFS Summer 2021, TIVIAN GmbH, Cologne, Germany).

The anonymized electronic clinical report form is the single access for each participating institution and is structured in different thematic pages, as follows: (1) identification, (2) demographics, (3) underlying diseases, (4) HM, (5) COVID-19, and (6) outcome.

Cases could be registered according to the following inclusion criteria: (1) age equal to or greater than 18 years, (2) history of active HM at any stage within the last 5 years before COVID-19, and (3) report of SARS-CoV-2 positive test documented by real-time reverse transcriptase polymerase chain reaction (RT-PCR) diagnostic panels.

Qualitative demographic and clinical data were described by frequencies and percentages, while medians and interquartile ranges (IQR) were used to summarize quantitative variables. Chi-square test, Fisher's exact test, and Mann-Whitney's *U* test were used for comparisons, as appropriate. Logistic and Cox multivariable regressions allowed to identify predictors of the outcomes.

SPSS software has been employed for the descriptive and inferential statistical analyses (SPSS, version 25.0, Chicago, IL, USA).

The reporting of this study conforms to the STROBE statement (www.equator-network.org/reporting-guidelines/strobe/).

Results

Overall, 398 MPN patients with COVID-19 were registered in EPICOVIDEHA from February 2020 to March 2022 (Table 1): 113 individuals (28.4%) with essential thrombocythemia (ET), 183 (46.0%) with myelofibrosis (MF), and 102 (25.6%) with polycythemia vera (PV). Thirty individuals were newly diagnosed MPN concomitantly or within 1 month from diagnosis of SARS-CoV-2 infection. Overall, 148 patients (37.2%) had received hydroxyurea as the most recent treatment before COVID-19, while 111 patients (27.9%) had received JAK inhibitors. More specifically, 92 MF patients (50.3%) and 17 PV patients (16.7%) were receiving JAK inhibitors, while 10 patients were receiving other therapies with an immunosuppressive potential, namely immunomodulating agents (IMiD), such as thalidomide or lenalidomide, or steroids. Overall, 121 patients (who did not have undergone transplantation) received therapies with an immunosuppressive potential: this corresponds to 30.4% of the overall cohort and 55.2% of the MF subgroup. Moreover, 8.3% of the overall cohort (33 patients) were refractory or resistant to ongoing

Rafael Duarte
Hospital Universitario
Puerta de Hierro,
Majadahonda, Spain

Rui Bergantim
Centro Hospitalar e
Universitário São João,
Porto, Portugal

Ozren Jaksic
University Hospital
Dubrava, Zagreb, Croatia

Natasha Čolović
University Clinical Center
Serbia, Medical Faculty
University Belgrade,
Belgrade, Serbia

Ola Blennow
Anna Nordlander
Department of Infectious
Diseases, Karolinska
University Hospital,
Stockholm, Sweden

Martin Cernan
University Hospital
Olomouc, Olomouc, Czech
Republic

Martin Schönlein
Department of Oncology,
Hematology and Bone
Marrow Transplantation
with Section of
Pneumology, University
Medical Center Hamburg-
Eppendorf, Hamburg,
Germany

Michail Samarkos
Laikon Hospital,
Athens, Greece

Maria Enza Mitra
UO Ematologia, AOUP P.
Giaccone, Palermo, Italy

Gabriele Magliano
ASST Grande Ospedale
Metropolitano Niguarda,
Milan, Italy

Johan Maertens
KU Leuven, Leuven,
Belgium

Marie-Pierre Ledoux
ICANS, Strasbourg, France

Moraima Jiménez
Alba Cabrita
Department of
Hematology, Vall d'Hebron
Hospital Universitari,
Experimental Hematology,
Vall d'Hebron Institute
of Oncology (VHIO), Vall
d'Hebron Barcelona
Hospital Campus,
Barcelona, Spain

Departament de Medicina,
Universitat Autònoma de
Barcelona, Bellaterra,
Spain

Fatih Demirkan
Division of Hematology,
Dokuz Eylül University,
Izmir, Turkey

Graham P. Collins
NIHR Oxford Biomedical
Research Centre,
Churchill Hospital,
Oxford, UK

Stefanie K. Gräfe
Universitätsklinikum
Hamburg-Eppendorf,
Hamburg, Germany
Department I of Internal
Medicine, Excellence
Center for Medical
Mycology (ECMM), Faculty
of Medicine and University
Hospital Cologne,
University of Cologne,
Cologne, Germany
Cologne Excellence
Cluster on Cellular Stress
Responses in Aging-
Associated Diseases
(CECAD), Faculty of
Medicine and University
Hospital Cologne,
University of Cologne,
Cologne, Germany

Elena Arellano
Department of
Hematology, University
Hospital Virgen Macarena,
Seville, Spain

Raul Cordoba
Health Research Institute
IIS-FJD, Fundacion
Jimenez Diaz University
Hospital, Madrid, Spain

Francesco Marchesi
Hematology and Stem Cell
Transplant Unit, IRCCS
Regina Elena National
Cancer Institute, Rome,
Italy

Oliver A. Cornely
Department I of Internal
Medicine, Excellence
Center for Medical
Mycology (ECMM), Faculty
of Medicine and University
Hospital Cologne,
University of Cologne,
Cologne, Germany
Chair Translational
Research, Cologne
Excellence Cluster on
Cellular Stress Responses
in Aging-Associated
Diseases (CECAD), Faculty
of Medicine and University
Hospital Cologne,
University of Cologne,
Cologne, Germany
Clinical Trials Centre
Cologne (ZKS Köln),
Faculty of Medicine
and University Hospital
Cologne, University
of Cologne, Cologne,
Germany
Center for Molecular
Medicine Cologne (CMMC),
Faculty of Medicine
and University Hospital
Cologne, University
of Cologne, Cologne,
Germany
German Centre for
Infection Research
(DZIF), Partner Site
Bonn-Cologne, Cologne,
Germany

Table 1. Baseline characteristics and outcomes according to the underlying malignancy.

	All MPN <i>n</i> = 398		Essential thrombocythemia <i>n</i> = 113		Myelofibrosis <i>n</i> = 183		Polycythemia vera <i>n</i> = 102	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Sex (male)	232	58.3	54	47.8	109	59.6	69	67.6
Age (median, IQR)								
<50 years old	52	13.1	27	23.9	16	8.7	9	8.8
51–69 years old	158	39.7	31	27.4	81	44.3	46	45.1
>70 years old	188	47.2	55	48.7	86	47.0	47	46.1
Comorbidities								
No comorbidities	155	38.9	49	43.4	59	32.2	47	46.1
1 comorbidity	130	32.7	37	32.7	62	33.9	31	30.4
2 comorbidities	73	18.3	21	18.6	36	19.7	16	15.7
≥3 comorbidities	40	10.1	6	5.3	26	14.2	8	7.8
Cardiovascular comorbidities	144	36.2	40	35.4	66	36.1	38	37.3
Diabetes mellitus	59	14.8	13	11.5	35	19.1	11	10.8
Smoking history	41	10.3	7	6.2	25	13.7	9	8.8
Disease status at COVID-19 onset								
Newly diagnosed	30	7.5	6	5.3	19	10.4	5	4.9
Refractory	33	8.3	2	1.8	25	13.7	6	5.9
Ongoing treatment – Drug therapies								
Hydroxyurea	148	37.2	66	58.4	32	17.5	50	49.0
JAK inhibitors	111	27.9	2	1.8	92	50.3	17	16.7
Immunosuppressive therapy	121	30.4	2	1.8	101	55.2	18	17.6
COVID-19 vaccination status								
At least one dose	80	20.1	21	18.6	41	22.4	18	17.6
COVID-19 severity								
Asymptomatic	66	16.6	25	22.1	23	12.6	18	17.6
Pulmonary symptoms	212	53.3	62	54.9	97	53.0	53	52.0
Severe/Critical	239	60.1	59	52.2	125	68.3	55	53.9
Hospital stay and management during COVID-19								
Hospital admission	216	54.3	49	43.4	114	62.3	53	52.0
Intensive care unit	53	13.3	8	7.1	32	17.5	13	12.7
Invasive ventilation	29	7.3	5	4.4	16	8.7	8	7.8
COVID-19 outcome								
Fatality rate	89	22.4	15	13.3	57	31.1	17	16.7

COVID-19, coronavirus disease 2019; IQR, interquartile range; *n*, number of patients; MPN, chronic myeloproliferative neoplasms.

therapies: the rate was lower in ET (1.8%), while it was higher in MF (13.7%). Overall, seven patients (1.7%) had received allogeneic hematopoietic stem cell transplant (HSCT): three of them were transplanted more than 6 months before COVID-19.

Males were 58.3% of the whole cohort and median age at infection was 69 years (IQR: 58–77, range: 22–97). Moreover, in 61.1% of the patients, at least one comorbidity was reported, while in 10.1%, three or more comorbidities were listed in the medical history checking seven ever major comorbidities, namely chronic cardiovascular and pulmonary diseases, renal failure, diabetes, liver diseases, obesity, and concurrent neoplasms. In particular, 144 patients (36.2%) suffered from cardiovascular diseases (e.g. atrial fibrillation, arterial hypertension, obstructive arteriopathy), 52 from chronic pulmonary disease (13.1%), 59 from diabetes (14.9%), 21 from liver disease (5.3%), 27 from obesity (6.8%), 18 from renal impairment (e.g. serum creatinine above 2 mg/dl) (4.5%). Smoking history was reported in 41 patients (10.3%).

Overall, 76 (19.1%) individuals had received at least two prior vaccination doses before COVID-19 and 37 (9.3%) had received three doses. Messenger ribonucleic acid (mRNA) vaccines were administered to 70 (17.6%) patients.

In a small portion of patients (16.6%), asymptomatic SARS-CoV-2 infection was documented, while cough or dyspnea was reported by most of the individuals (53.3%). Both extrapulmonary and pulmonary symptoms were observed in 66 individuals (21.9%) and exclusively extrapulmonary symptoms in 65 (23.4%).

Overall, 216 patients (54.3%) were admitted to hospital and the median duration of hospital stay was 14 days (IQR: 6–22, range: 1–90). Univariable logistic regression identified MPN-related and unrelated clinical factors significantly related to the chance of hospitalization (Table 2). Among MPN-related factors, MF and exposure to immunosuppressive therapies were the most important variables, while among MPN-unrelated factors, age >70 years, cardiopathy, and number of comorbidities appeared to be linked to hospitalization. In multivariable regression analysis, exposure to immunosuppressive agents remained an independent

predictor of the risk of hospital admission for MPN patients with COVID-19 [odds ratio (OR): 2.186; 95% confidence interval (CI): 1.357–3.519] and so was age >70 years (OR: 2.636; 95% CI: 1.683–4.129). However, prior exposure to ruxolitinib was not by itself an independent predictor of hospital admission.

Overall, 53 out of 216 hospitalized patients were admitted to intensive care unit (ICU) (24.5%) and mechanical ventilation was required for 29 patients (13.4%). The rate of admission to ICU was significantly higher in MF compared with the other MPN subtypes: 17.5% of the overall MF patients required ICU support *versus* 7.1% of patients with ET patients. Median length of the ICU stay was 10 days (IQR: 5–18).

MPN patients were followed for a median of 76 days (IQR: 19–197) and the reported mortality rate was 22.4%, which declined gradually over the time of the COVID-19 pandemic. During the first half of the year 2020, it was 38.9% (49 out of 126 patents), declining to 17.6% (27 out of 153) during the second half of 2020 subsequently further dropping down to 10.9% from 2021 on ($p < 0.001$) (Figures 1 and 2). Death occurred after a median of 14 days (IQR: 8–49) upon diagnosis of infection and was principally attributable to COVID-19 in 68 patients (76.4%) and contributable by COVID-19 in 10 (11.2%).

Multivariable Cox regression analysis revealed that age >70 years was an independent predictor of mortality [hazard ratio (HR): 2.191; 95% CI: 1.363–3.521], as well as comorbidity burden (Table 3). Mortality varied among MPN diseases from 13.3% in patients with ET to 31.1% in those with MF. Exposure to immunosuppressive agents before SARS-CoV-2 infection was an independent predictor of death (HR: 2.143; 95% CI: 1.369–3.354) (Table 3), as was the exposure to ruxolitinib (HR: 2.161; 95% CI: 1.381–3.354). A sub-analysis of 155 MF patients receiving active pharmacologic treatment for their disease before COVID-19 suggested that those exposed to immunosuppressive therapies might have an inferior survival compared with those receiving any other type of treatment ($p = 0.059$).

Multivariable Cox regression analysis of mortality reported similar results after including time from MPN diagnosis and COVID-19 infection wave (Table 4). Similarly, exposure

Livio Pagano
Hematology Unit,
Fondazione Policlinico
Universitario Agostino
Gemelli-IRCCS, Rome,
Italy

Hematology Unit,
Università Cattolica del
Sacro Cuore, Rome, Italy

*MM and JS-G are shared
junior authors.

Table 2. Logistic regression analysis of hospital admission.

	Univariate analysis				Multivariate analysis			
	<i>p</i> value	OR	95% CI lower limit	95% CI upper limit	<i>p</i> value	OR	95% CI lower limit	95% CI upper limit
Age								
<70 years old	-	-	-	-	-	-	-	-
≥70 years old	<0.001	3.091	2.046	4.67	<0.001	2.636	1.683	4.129
Immunosuppressive therapies								
Cytoreductive drug therapy	-	-	-	-	-	-	-	-
Immunosuppressive cytoreductive drug therapy	<0.001	2.134	1.363	3.34	0.001	2.186	1.357	3.519
No cytoreductive or immunosuppressive drug therapy	0.321	1.370	0.735	2.554	0.222	1.519	0.776	2.971
Malignancy								
Essential thrombocythemia	-	-	-	-	-	-	-	-
Myelofibrosis	0.002	2.158	1.339	3.478	0.147	1.564	0.854	2.864
Polycythemia vera	0.208	1.413	0.825	2.419	0.231	1.427	0.798	2.553
Comorbidities								
No comorbidities	-	-	-	-	-	-	-	-
1 comorbidity	<0.001	2.603	1.612	4.205	0.005	2.060	1.241	3.418
2 comorbidities	<0.001	3.124	1.746	5.591	0.016	2.146	1.156	3.982
3 or more comorbidities	<0.001	4.290	1.994	9.228	0.009	2.932	1.313	6.548
Cardiopathy	<0.001	2.233	1.460	3.416	-	-	-	-

CI, confidence interval; OR, odds ratio.

to immunosuppressive drugs independently predicted a higher hospitalization rate irrespective of the infection wave and time from MPN diagnosis (Table 5).

Discussion

MPN is a heterogeneous family of diseases particularly prone to thrombosis and bleeding, but also to infections and secondary neoplasms due to dysregulated innate and adaptive immunity. Spleen neoangiogenesis and chronic inflammation driven by MPN-specific mutations (e.g. JAK2 V617F) are hypothesized to be

the underlying substrates for the above clinical manifestations.^{6,7,9-13} MPN phenotypes largely vary upon age at disease presentation, and therapies for MPN may specifically modulate the risk of thrombosis, infections, and secondary neoplasms.¹⁴ Moreover, registry-based propensity-adjusted studies and two meta-analyses registered an increased risk of infections, mostly viral, in patients treated with the JAK2/2 inhibitor ruxolitinib.¹⁵⁻¹⁷ We, therefore, aimed to assess whether the exposure to ‘immunosuppressive’ therapies, namely JAK inhibitors, IMiDs, or steroids, might aggravate the clinical course of COVID-19 in MPN patients. As a consequence, we performed




Figure 1. COVID-19 mortality rate in different time periods. The bars report percent mortality of MPN patients with COVID-19 infection in consecutive quarters from first 2020 quarter to first 2022 quarter.




Figure 2. Survival curves after SARS-CoV-2 infection according to the period. The line shows the survival after COVID-19 in the first wave, while orange, yellow, and green lines show subsequent waves. The rectangle reports p values for pairwise comparisons.

a specific query to the EPICVIDEHA registry, which had previously reported very high admission rates to hospital (73.1%) and to ICU (18.1%) and mortality (31.2%) in the 3801 patients surveyed during the year 2020.^{8,18}

As of 31 March 2022, overall, 398 MPN patients were reported by the EPICVIDEHA survey: 46.0% of the patients suffered from MF, 30.4% were on immunosuppressive therapies (JAK inhibitors, steroids, or IMiDs), 47.2% were above

Table 3. Cox regression analysis of fatality rate.

	Univariable analysis				Multivariable analysis			
	<i>p</i> value	HR	95% CI lower limit	95% CI upper limit	<i>p</i> value	HR	95% CI lower limit	95% CI upper limit
Age								
<70 years old	-	-	-	-	-	-	-	-
≥70 years old	<0.001	2.877	1.837	4.504	0.001	2.191	1.363	3.521
Immunosuppressive therapies								
Cytoreductive drug therapy	-	-	-	-	-	-	-	-
Immunosuppressive drug therapy	<0.001	2.156	1.389	3.345	<0.001	2.143	1.369	3.354
No cytoreductive or immunosuppressive drug therapy	0.891	1.052	0.509	2.177	0.944	0.974	0.466	2.037
Malignancy								
Essential thrombocythemia	-	-	-	-	-	-	-	-
Myelofibrosis	<0.001	2.644	1.496	4.673	0.073	1.888	0.944	3.779
Polycythemia vera	0.463	1.297	0.647	2.598	0.312	1.443	0.709	2.937
Comorbidities								
No comorbidities	-	-	-	-	-	-	-	-
1 comorbidity	0.003	2.485	1.353	4.564	0.033	1.967	1.056	3.663
2 comorbidities	<0.001	3.176	1.667	6.049	0.009	2.441	1.247	4.780
3 or more comorbidities	<0.001	8.000	4.154	15.408	<0.001	5.487	2.765	10.889
Cardiopathy	<0.001	2.468	1.625	3.750	-	-	-	-

CI, confidence interval; HR, hazard ratio.

70 years of age, and 10.1% suffered from at least three comorbidities. Out of the overall MPN cohort, 54.3% were admitted to hospital, 13.3% were admitted to ICU, and 22.4% deceased. The outcomes of infection varied according to the underlying disease, MF being associated with the highest rates of hospitalization.¹⁹ COVID-19 outcomes were worsened by previous exposure to immunosuppressive therapies before infection onset. Exposure to immunosuppressive agents independently increased the risk of both hospitalization (OR: 2.186; 95% CI: 1.357–3.519) and mortality (HR: 2.143; 95% CI: 1.369–3.354) and

exposure to ruxolitinib was an independent predictor of mortality (HR: 2.161; 95% CI: 1.381–3.379).

JAK inhibitors have been reported to ameliorate systemic inflammation driven by SARS-CoV-2 and have even been proposed as potential therapeutic principles also for patients without MPN.²⁰ However, based on the broad immunosuppressive potential of JAK inhibitors (in particular, of ruxolitinib), longer exposure to ruxolitinib limits T-cell and humoral responses to BNT162b2 (Pfizer/BioNTech®) and mRNA-1273 (Moderna®)

Table 4. Cox regression analysis of fatality rate including the pandemic wave and disease duration.

	Univariable analysis				Multivariable analysis			
	<i>p</i> value	HR	95% CI lower limit	95% CI upper limit	<i>p</i> value	HR	95% CI lower limit	95% CI upper limit
Age								
<70 years old	–	–	–	–	–	–	–	–
≥70 years old	<0.001	2.877	1.837	4.504	<0.001	2.285	1.408	3.708
Immunosuppressive therapies								
Cytoreductive drug therapy	–	–	–	–	–	–	–	–
Immunosuppressive drug therapy	<0.001	2.16	1.389	3.345	<0.001	2.19	1.394	3.443
No cytoreductive or immunosuppressive drug therapy	0.891	1.05	0.509	2.177	0.594	0.82	0.387	1.721
Malignancy								
Essential thrombocythemia	–	–	–	–	–	–	–	–
Myelofibrosis	<0.001	2.644	1.496	4.673	0.034	2.151	1.061	4.363
Polycythemia vera	0.463	1.297	0.647	2.598	0.216	1.572	0.767	3.220
Months from malignancy (diagnosis) to COVID-19	0.564	0.999	0.996	1.002	–	–	–	–
Comorbidities ^a								
No comorbidities	–	–	–	–	–	–	–	–
1 comorbidity	0.003	2.485	1.353	4.564	0.052	1.873	0.994	3.528
2 comorbidities	<0.001	3.176	1.667	6.049	0.039	2.078	1.039	4.157
3 or more comorbidities	<0.001	8.000	4.154	15.408	<0.001	4.723	2.338	9.540
Pandemic wave								
2020 Q1–Q2	–	–	–	–	–	–	–	–
2020 Q3–Q4	0.004	0.492	0.305	0.793	0.031	0.584	0.359	0.951
2021 Q1–Q2	0.097	0.421	0.152	1.170	0.119	0.440	0.157	1.234
2021 Q3–Q4	0.047	0.390	0.154	0.989	0.099	0.450	0.174	1.162
2022 Q1	0.083	0.400	0.142	1.128	0.049	0.349	0.122	0.995

CI, confidence interval; COVID-19, coronavirus disease 2019; HR, hazard ratio.

^aSingle comorbidities with statistically significant predictive value uniquely at univariate analysis included chronic cardiopathy (HR: 0.468; 95% CI: 1.625–3.750), chronic pulmonary disease (HR: 2.346; 95% CI: 1.438–3.829), diabetes mellitus (HR: 2.793; 95% CI: 1.758–4.438), liver disease (HR: 2.527; 95% CI: 1.217–5.247), and renal impairment (HR: 4.112; 95% CI: 2.178–7.763).

Table 5. Logistic regression analysis of hospital admission including the pandemic wave and disease duration.

	Univariate analysis				Multivariate analysis			
	p value	OR	95% CI lower limit	95% CI upper limit	p value	OR	95% CI lower limit	95% CI upper limit
Age								
<70 years old	-	-	-	-	-	-	-	-
≥70 years old	<0.001	3.091	2.046	4.670	<0.001	2.894	1.782	4.700
Immunosuppressive therapies								
Cytoreductive drug therapy	-	-	-	-	-	-	-	-
Immunosuppressive drug therapy	<0.001	2.134	1.363	3.34	<0.001	2.428	1.458	4.043
No cytoreductive or immunosuppressive drug therapy	0.321	1.37	0.735	2.554	0.672	1.175	0.557	2.48
Malignancy								
Essential thrombocythemia	-	-	-	-	-	-	-	-
Myelofibrosis	0.002	2.158	1.339	3.478	0.089	1.770	0.918	3.415
Polycythemia vera	0.208	1.413	0.825	2.419	0.213	1.498	0.793	2.832
Months from malignancy (diagnosis) to COVID-19	0.845	1.000	0.997	1.003				
Comorbidities^a								
No comorbidities	-	-	-	-	-	-	-	-
1 comorbidity	<0.001	2.603	1.612	4.205	0.010	2.047	1.183	3.539
2 comorbidities	<0.001	3.124	1.746	5.591	0.124	1.679	0.867	3.251
3 or more comorbidities	<0.001	4.290	1.994	9.228	0.026	2.652	1.121	6.273
Pandemic wave								
2020 Q1-Q2	-	-	-	-	-	-	-	-
2020 Q3-Q4	<0.001	0.241	0.142	0.408	<0.001	0.266	0.151	0.469
2021 Q1-Q2	0.117	0.476	0.188	1.203	0.127	0.460	0.170	1.247
2021 Q3-Q4	<0.001	0.143	0.068	0.302	<0.001	0.131	0.058	0.298
2022 Q1	<0.001	0.161	0.079	0.328	<0.001	0.119	0.054	0.264

CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio; HR, hazard ratio.

^aStatistically significant comorbidities only at univariate analysis: chronic cardiopathy (OR: 2.23; 95% CI: 1.460–3.416), chronic pulmonary disease (OR: 2.301; 95% CI: 1.218–4.347), diabetes mellitus (OR: 3.158; 95% CI: 1.671–5.968).

SARS-CoV-2 vaccines.^{21–29} Moreover, ruxolitinib discontinuation has recently reported to be associated with worse outcome in SARS-CoV-2-infected MPN patients.¹⁹ At this first analysis of the EPICOVIDEHA MPN cohort, we could not ascertain whether worse outcomes were most attributable to interruption of immunosuppressive therapies; however, we planned to better address these issues in subsequent enquiries.

The COVID-19 vaccination campaign has led to a reduction in hospitalization rate and mortality, but risks are still high in patients with blood cancers. Further primary preventive strategies for frail patients include administration of fourth vaccination dose and long-life monoclonal agents, such as tixagevibam *plus* cilgavimab.^{29–31} While immune response to vaccination is still being ascertained in patients with HM and may vary according to the prevalent viral variant, long-life monoclonal agents in European Union are currently being restricted to patients undergoing cell therapy.^{31–33} This study enrolled many patients involved by the first SARS-CoV-2 waves and thus a very low percentage of patients had received at least one vaccine dose. The present report also suggests to devote intensified preventive measures to patients with MPN receiving immunosuppressive agents.

There are limitations of our study that must be acknowledged. First, MF patients are likely to be slightly overrepresented in our series, but we could not attribute this skewness to the higher severity of COVID-19 in MF patients. Second, as we included patients from different countries and centers, and diagnosed in different waves of the pandemic, a certain heterogeneity in our data is to be expected. In addition, only a small number of patients in this series were vaccinated: this is due to the fact that most data were collected during early waves, where vaccinations were not broadly available. Furthermore, SARS-CoV-2 vaccination was reported to be effective in patients with MPN; therefore, a few breakthrough infections are expected to occur. Another limitation of the study relates to data on outcome and survival, which must be interpreted carefully, since from the limited data forms, we could not ascertain any covariate that was correlated with JAK-inhibitor therapy and that might explain the inferior outcome. In particular, receiving immunosuppressive drugs may be related to advanced disease stage. Moreover, thromboembolic events after

COVID-19 infection could not be accurately tracked by the study, which may hamper a definite analysis of the causes of death. Finally, abrupt interruption of, rather than prior exposure to, JAK inhibitors might explain the higher FR in hospitalized patients; however, this information was not required in the former data collection form and is currently not available.

For the above reasons, future data collection will be focused on drug–outcome relationships in a fully vaccinated population and will explore COVID-19 outcome in patients treated with JAK inhibitors, considering disease severity and therapy discontinuation among the covariates.

Conclusion

In conclusion, the present study confirmed dismal outcomes in the older MPN patients and in those with higher comorbidity burden, (i.e. cardiovascular or pulmonary disease or diabetes). In addition, to the best of our knowledge, this study is the first reporting that exposure to immunosuppressive agents before SARS-CoV-2 infection independently increased hospitalization rates and risk of death. Specific preventive strategies need, thus, to be tailored for these individuals at risk, including application of potentially protective preventive antibody cocktails as well as mindful tapering strategies in MPN patients pre-treated with JAK inhibitors. Finally, therapeutic decisions in the future should also consider the abovementioned risk factors.

Declarations

Ethics approval and consent to participate

Institutional Review Board and Ethics Committee of Fondazione Policlinico Universitario A. Gemelli – IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy (Study ID: 3226).

Consent for publication

All the authors agreed for publication of the manuscript in its present form.

Patient consent was managed according to local approval.

Author contributions

Monia Marchetti: Conceptualization; Investigation; Methodology; Writing – original draft; Writing – review & editing.

- Jon Salmanton-García:** Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing – review & editing.
- Shaimaa El-Ashwah:** Resources; Writing – review & editing.
- Luisa Verga:** Resources; Writing – review & editing.
- Federico Itri:** Resources; Writing – review & editing.
- Zdeněk Ráčil:** Resources; Writing – review & editing.
- Julio Dávila-Valls:** Resources; Writing – review & editing.
- Sonia Martín-Pérez:** Resources; Writing – review & editing.
- Jaap Van Doesum:** Resources; Writing – review & editing.
- Francesco Passamonti:** Resources.
- Ghaith Abu-Zeinah:** Resources; Writing – review & editing.
- Francesca Farina:** Resources; Writing – review & editing.
- Alberto López-García:** Resources; Writing – review & editing.
- Giulia Dragonetti:** Resources; Writing – review & editing.
- Chiara Cattaneo:** Resources; Writing – review & editing.
- Maria Gomes Da Silva:** Resources; Writing – review & editing.
- Yavuz M. Bilgin:** Resources; Writing – review & editing.
- Pavel Žák:** Resources; Writing – review & editing.
- Verena Petzer:** Resources; Writing – review & editing.
- Andreas Glenthøj:** Resources; Writing – review & editing.
- Ildefonso Espigado:** Resources; Writing – review & editing.
- Caterina Buquicchio:** Resources; Writing – review & editing.
- Valentina Bonuomo:** Resources; Writing – review & editing.
- Lucia Prezioso:** Resources; Writing – review & editing.
- Stef Meers:** Resources; Writing – review & editing.
- Rafael Duarte:** Resources; Writing – review & editing.
- Rui Bergantim:** Resources; Writing – review & editing.
- Ozren Jaksic:** Resources; Writing – review & editing.
- Natasha Čolović:** Resources; Writing – review & editing.
- Ola Blennow:** Resources; Writing – review & editing.
- Martin Cernan:** Resources; Writing – review & editing.
- Martin Schönlein:** Resources; Writing – review & editing.
- Michail Samarkos:** Resources; Writing – review & editing.
- Maria Enza Mitra:** Resources; Writing – review & editing.
- Gabriele Magliano:** Resources; Writing – review & editing.
- Johan Maertens:** Resources; Writing – review & editing.
- Marie-Pierre Ledoux:** Resources; Writing – review & editing.
- Moraima Jiménez:** Resources; Writing – review & editing.
- Fatih Demirkan:** Resources; Writing – review & editing.
- Graham P. Collins:** Resources; Writing – review & editing.
- Alba Cabirta:** Resources; Writing – review & editing.
- Stefanie K. Gräfe:** Resources; Writing – review & editing.
- Anna Nordlander:** Resources; Writing – review & editing.
- Dominik Wolf:** Resources; Writing – review & editing.
- Elena Arellano:** Resources; Writing – review & editing.

Raul Cordoba: Resources; Writing – review & editing.

Michaela Hanakova: Resources; Writing – review & editing.

Giovanni Paolo Maria Zambrotta: Resources; Writing – review & editing.

Raquel Nunes Rodrigues: Resources; Writing – review & editing.

Giulia Limberti: Resources; Writing – review & editing.

Francesco Marchesi: Resources; Supervision; Validation; Writing – review & editing.

Oliver A. Cornely: Funding acquisition; Resources; Supervision; Writing – review & editing.

Livio Pagano: Funding acquisition; Resources; Supervision; Writing – review & editing.

Acknowledgements

Toni Valkovič, Christian Bjørn Poulsen, Klára Piukovics, Monica Piedimonte, Irati Ormazabal-Vélez, Hans-Beier Ommen, Joseph Meletiadiis, Maria Stamouli, Marina Machado, Austin Kulasekararaj, Carolina Garcia-Vidal, Nicola Fracchiolla, María Fernández-Galán, Noemí Fernández, Rita Fazi, Alessandro Busca, Marcio Nucci, Milan Navrátil, Carolina Miranda-Castillo, Nick De Jonge, Michelina Dargenio, Annarosa Cuccaro, Barbora Weinbergerová, Jens Van Praet, Zlate Stojanoski, Uluhan Sili, Guldane Cengiz Seval, Ikhwan Rinaldi, László Imre Pinczés, Jan Novák, Jorge Loureiro-Amigo, Lisset Lorenzo De La Peña, Tobias Lahmer, Jorge Labrador, Nina Khanna, Maria-Josefa Jiménez-Lorenzo, Anna Guidetti, Tomás-José González-López, Iker Falces-Romero, Maria Ilaria Del Principe, Cristina De Ramón, François Danion, Nicola Coppola, Maria Calbacho, Nathan Bahr, Natasha Ali, Osman Ilhan, Ramón García-Sanz, Josep Maria Ribera-Santassusana, Agostino Tafuri, Nicole García-Poutón, Sofia Zompì, Mariarita Sciumè.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).

Competing interests

The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JSG reports speaker honoraria from Gilead and Pfizer, outside of the submitted work. DW received speakers honorary and research funding from Novartis, AOP Pharma, Incyte, Bexxalta, BMS/Celgene, outside of the submitted work. MM received consultancy fees from Gilead, outside of the submitted work. OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allegra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7), outside of the submitted work. No relevant conflicts of interest are reported by all the other authors.

Availability of data and materials

For data sharing, please contact the corresponding author.

ORCID iDs

Jon Salmanton-García  <https://orcid.org/0000-0002-6766-8297>

Graham P. Collins  <https://orcid.org/0000-0002-8803-4234>


References

1. World Health Organization. Pneumonia of unknown cause, 2020, <https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/> (accessed 31 March 2021).
2. Marchetti M. COVID-19 endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure. *Ann Hematol* 2020; 99: 1701–1707.

3. Acar HC, Can G, Karaali R, *et al.* An easy-to-use nomogram for predicting in-hospital mortality risk on COVID-19: a retrospective cohort study in a university hospital. *BMC Infect Dis* 2021; 21: 148.
4. Passamonti F, Cattaneo C, Arcaini L, *et al.* Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Hematol* 2021; 7: e737–e745.
5. Shallis RM, Wang R, Davidoff A, *et al.* Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. *Blood Rev* 2020; 42: 100706.
6. Hultcrantz M, Lung SH, Andersson TM-L, Björkholm M, *et al.* Myeloproliferative neoplasms and infections: a population-based study on 9,665 patients with myeloproliferative neoplasms diagnosed in Sweden 1987–2009. *Haematologica* 2015; 100: 260.
7. Hultcrantz M, Björkholm M, Dickman PW, *et al.* Risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. *Ann Intern Med* 2018; 168: 317–325.
8. Salamanton-García J, Busca A, Cornely OA, *et al.* EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID-19. *Hemasphere* 2021; 5: e612.
9. Marchetti M, Ghirardi A, Masciulli A, *et al.* Second cancers in MPN: survival analysis from an international study. *Am J Hematol* 2020; 95: 295–301.
10. Marchetti M, Carobbio A, Capitoni E, *et al.* Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review. *Am J Hematol* 2018; 93: 698–703.
11. De Stefano V, Ghirardi A, Masciulli A, *et al.* Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. *Blood* 2020; 135: 381–386.
12. Barosi G, Rosti V, Massa M, *et al.* Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. *Br J Haematol* 2004; 124: 618–625.
13. Cattaneo D and Iurlo A. Immune dysregulation and infectious complications in MPN patients treated with JAK inhibitors. *Front Immunol* 2021; 12: 750346.
14. Cervantes F, Barosi G, Hernández-Boluda JC, *et al.* Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. *Eur J Haematol* 2001; 66: 324–327.
15. Luo Q, Xiao Z and Peng L. Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis. *Hematology* 2021; 26: 663–669.
16. Lussana F, Cattaneo M, Rambaldi A, *et al.* Ruxolitinib-associated infections: a systematic review and meta-analysis. *Am J Hematol* 2018; 93: 339–347.
17. Tremblay D, King A, Li L, *et al.* Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. *Leuk Lymphoma* 2020; 61: 660–667.
18. Pagano L, Salamanton-García J, Marchesi F, *et al.* COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). *J Hematol Oncol* 2021; 14: 168.
19. Barbui T, Iurlo A, Masciulli A, *et al.* Second versus first wave of COVID-19 in patients with MPN. *Leukemia* 2022; 36: 897–900.
20. Kalil AC, Patterson TF, Mehta AK, *et al.* Baricitinib plus remdesivir for hospitalized adults with COVID-19. *N Engl J Med* 2021; 384: 795–807.
21. Gatti M, Turrini E, Raschi R, *et al.* Janus Kinase inhibitors and coronavirus disease (COVID-19): rational, clinical evidence and safety issues. *Pharmaceuticals* 2021; 14: 738.
22. Cattaneo D, Bucelli C, Cavallaro F, *et al.* Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience. *Blood Cancer J* 2021; 11: 185.
23. Pimpinelli F, Marchesi F, Piaggio G, *et al.* Lower response to BNT 162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. *J Hematol Oncol* 2021; 14: 119.
24. How J, Gallagher KME, Liu Y, *et al.* Antibody and T-cell response to COVID-19 vaccination in myeloproliferative neoplasm patients. *Blood* 2021; 138: 316.
25. Heine A, Held SAE, Daecke SN, *et al.* The JAK-inhibitor ruxolitinib impairs dendritic cell

- function in vitro and in vivo. *Onkologie* 2013; 36: 215–216.
26. Schönberg K, Rudolph J, Vonnahme M, *et al.* JAK inhibition impairs NK cell function in myeloproliferative neoplasms. *Cancer Res* 2015; 75: 2187–2199.
27. Parampalli Yajnanarayana S, Stübiger T, Cornez I, *et al.* JAK 1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. *Br J Haematol* 2015; 169: 824–833.
28. Scölein M, Wrage V, Ghandili S, *et al.* Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study. *Cancer Cell* 2022; 40: 581–583.
29. Caocci G, Mulas O, Mantovani D, *et al.* Should be a third dose of BNP162b2 mRNA COVID-19-vaccine administered in patients with myelofibrosis under ruxolitinib? *Blood* 2021; 138: 2573.
30. Regev-Yochay G, Gonen T, Gilboa M, *et al.* Efficacy of a fourth dose of COVID-19 mRNA vaccine against Omicron. *N Engl J Med* 2022; 386: 1377–1380.
31. European Medicines Agency (EMA). EMA recommends authorisation of COVID-19 medicine Evusheld. *European Medicines Agency (EMA)*, 24 March 2022, <https://www.ema.europa.eu/en/news/ema-recommends-authorisation-covid-19-medicine-evusheld> (accessed 12 April 2022).
32. Gong I, Vijenthira A, Betschel S, *et al.* COVID-19 vaccine response in patients with hematologic malignancy: a systematic review and meta-analysis. *Blood* 2021; 138: 4113.
33. Borgogna C, Bruna R, Griffante G, *et al.* Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients. *Blood Cancer J* 2022; 12: 8.

Visit SAGE journals online
[journals.sagepub.com/
home/tah](https://journals.sagepub.com/home/tah)

 SAGE journals